MSD

News

With Merck circling, SpringWorks gets new drug approval

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

News

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.

News

MSD buys Irish vaccines plant from WuXi for €500m

MSD has expanded its presence in Ireland with an agreement to buy a vaccines manufacturing facility from WuXi Biologics in Dundalk.

News

MSD makes its obesity move with $2bn Hansoh deal

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

News

Adult holding the hand of a newborn baby

MSD eyes June verdict for paediatric RSV antibody

The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year.

News

End of the line for MSD's TIGIT, LAG-3 cancer drugs

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

With Merck circling, SpringWorks gets new drug approval

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD buys Irish vaccines plant from WuXi for €500m

MSD makes its obesity move with $2bn Hansoh deal

MSD eyes June verdict for paediatric RSV antibody

End of the line for MSD's TIGIT, LAG-3 cancer drugs

Gilead, MSD share data on once-weekly oral HIV treatment

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks